Keyphrases
Abrocitinib
85%
Moderate-to-severe Atopic Dermatitis
72%
Atopic Dermatitis
57%
Itch
43%
Placebo
32%
Dupilumab
32%
Monotherapy
30%
Quality of Life
26%
Basal Cell Carcinoma
26%
Rapid Improvement
24%
5-fluorouracil (5-FU)
24%
Dermatological Diseases
24%
Investigator's Global Assessment
24%
Area Index
22%
Severity Index
22%
Eczema
22%
Once-daily
21%
Upadacitinib
19%
Janus Kinase 1 (JAK1)
19%
Forearm
18%
Actinic Keratosis
17%
Randomized Controlled Trial
17%
Hydroxychloroquine
16%
Skin Cancer
16%
Non-responders
15%
Clinical Outcomes
15%
Confocal Microscopy
15%
Pruritus
15%
Dermatologic Surgery
14%
Systematic Literature Review
13%
Topical Corticosteroids
12%
Plaque Psoriasis
12%
Intralesional
12%
Contemporary Approaches
12%
Pilocarpine Model
12%
Pathophysiology
12%
Laser-assisted
12%
Reflectance Confocal Microscopy
12%
Tapinarof
12%
Disease Association
12%
Epidemiology
12%
Ulcer
12%
Systemic Therapy
12%
Surgical Scar
12%
Ectopic Granule Cell
12%
Network Meta-analysis
12%
Dermatological Adverse Effects
12%
Diagnosis Treatment
12%
Clinical Subtypes
12%
Efficacy Outcomes
12%
Medicine and Dentistry
Dermatological Agent
44%
Disease
32%
Pruritus
27%
Basal-Cell Carcinoma
26%
Atopic Dermatitis
26%
Systematic Review
26%
Fluorouracil
24%
Placebo
21%
Health Care Cost
19%
Skin Surgery
18%
Skin Cancer
18%
Actinic Keratosis
18%
Adverse Event
16%
Patient-Reported Outcome
14%
Confocal Microscopy
13%
Disease Association
12%
Mohs Surgery
12%
Subgroup Analysis
12%
Pemetrexed
12%
Cohort Effect
12%
Lentigo Maligna
12%
Reflectance Confocal Microscopy
12%
Tapinarof
12%
Ulcer
12%
Arm
12%
Patient Experience
12%
Dupilumab
12%
Psoriasis Vulgaris
12%
Pathophysiology
12%
Molecularly Targeted Therapy
12%
Full Thickness Skin Graft
12%
Suture
12%
Melanoma
12%
Diseases
12%
Physical Examination
10%
Eczema
9%
Quality of Life
8%
Malignant Neoplasm
8%
Continuing Medical Education
8%
Dermatology Life Quality Index
6%
Topical Corticosteroid
6%
Pigmentation
6%
Induction Chemotherapy
6%
Papule
6%
Infusion
6%
Patient Care
6%
Back
6%
Sunscreen
6%
Chemotherapy
6%
Erythema
6%
Pharmacology, Toxicology and Pharmaceutical Science
Atopic Dermatitis
100%
Pruritus
55%
Placebo
46%
Disease
40%
Dupilumab
32%
Monotherapy
31%
Dermatological Agent
26%
Basal Cell Carcinoma
26%
Eczema
23%
Adverse Event
23%
Malignant Neoplasm
20%
Upadacitinib
18%
Physical Disease by Body Function
15%
Squamous Cell Carcinoma
14%
Randomized Controlled Trial
14%
Disease Association
12%
Topical Corticosteroid
12%
Psoriasis Vulgaris
12%
Pathophysiology
12%
Tapinarof
12%
Toxic Epidermal Necrolysis
12%
Rhizopus
12%
Fluorouracil
12%
Hydroxychloroquine
12%
Papillomavirus Infection
12%
Human Papillomavirus
9%
Janus Kinase 1
7%
Combination Therapy
6%